KETOROLAC TROMETHAMINE
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- KETOROLAC TROMETHAMINE
- Generic name
- KETOROLAC TROMETHAMINE
- Manufacturer
- PD-Rx Pharmaceuticals, Inc.
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- 862dd7b7-8ed5-42bf-870e-a45b86740226
- SPL ID
- 5f66aa68-cb95-e3c9-e063-6294a90a1ea3
- Version
- 13
- Effective date
- 2026-11-03
- Source export date
- 2026-11-13
- Source partition
- 2
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0002-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/3b4204ed830f35b16ab24b2123672d7d93066eb0fd8af1cf09b223d0e4568221/drug-label-0002-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 15:31:52
| Harmonized routes |
|---|
| ORAL |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | ANDA | 215745 | derived:openfda.application_number |
| application number | ANDA215745 | openfda.application_number | |
| brand name | KETOROLAC TROMETHAMINE | openfda.brand_name | |
| generic name | KETOROLAC TROMETHAMINE | openfda.generic_name | |
| manufacturer name | PD-Rx Pharmaceuticals, Inc. | openfda.manufacturer_name | |
| ndc | package | 72789-437-01 | openfda.package_ndc |
| ndc | package | 72789-437-20 | openfda.package_ndc |
| ndc | package | 72789-437-10 | openfda.package_ndc |
| ndc | product | 72789-437 | openfda.product_ndc |
| ndc11 | package | 72789043701 | derived:openfda.package_ndc |
| ndc11 | package | 72789043710 | derived:openfda.package_ndc |
| ndc11 | package | 72789043720 | derived:openfda.package_ndc |
| rxcui | 834022 | openfda.rxcui | |
| spl id | 5f66aa68-cb95-e3c9-e063-6294a90a1ea3 | id | |
| spl set id | 862dd7b7-8ed5-42bf-870e-a45b86740226 | set_id | |
| unii | 4EVE5946BQ | openfda.unii |
Boxed warning cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
WARNING Ketorolac tromethamine tablets, a nonsteroidal anti-inflammatory drug (NSAID), are indicated for the short-term (up to 5 days in adults), management of moderately severe acute pain that requires analgesia at the opioid level and only as continuation treatment following IV or IM dosing of ketorolac tromethamine, if necessary. The total combined duration of use of ketorolac tromethamine tablets and ketorolac tromethamine should not exceed 5 days. Ketorolac tromethamine tablets are not indicated for use in pediatric patients and they are NOT indicated for minor or chronic painful conditions. Increasing the dose of ketorolac tromethamine tablets beyond a daily maximum of 40 mg in adults will not provide better efficacy but will increase the risk of developing serious adverse events. GASTROINTESTINAL RISK Ketorolac tromethamine, including ketorolac tromethamine tablets can cause peptic ulcers, gastrointestinal bleeding and/or perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Therefore, ketorolac tromethamine is CONTRAINDICATED in patients with active peptic ulcer disease, in patients with recent gastrointestinal bleeding or perforation, and in patients with a history of peptic ulcer disease or gastrointestinal bleeding. Elderly patients are at greater risk for serious gastrointestinal events (see WARNINGS ). CARDIOVASCULAR THOMBOTIC EVENTS Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use (see WARNINGS and PRECAUTIONS ). Ketorolac tromethamine tablets are contraindicated in the setting of coronary artery bypass graft (CABG) surgery (see CONTRAINDICATIONS and WARNINGS ). RENAL RISK Ketorolac tromethamine is CONTRAINDICATED in patients with advanced renal impairment and in patients at risk for renal failure due to volume depletion (see WARNINGS ). RISK OF BLEEDING Ketorolac tromethamine inhibits platelet function and is, therefore, CONTRAINDICATED in patients with suspected or confirmed cerebrovascular bleeding, patients with hemorrhagic diathesis, incomplete hemostasis and those at high risk of bleeding (see WARNINGS and PRECAUTIONS ). Ketorolac tromethamine is CONTRAINDICATED as prophylactic analgesic before any major surgery. RISK DURING LABOR AND DELIVERY The use of ketorolac tromethamine in labor and delivery is contraindicated because it may adversely affect fetal circulation and inhibit uterine contractions. CONCOMITANT USE WITH NSAIDS Ketorolac tromethamine is contraindicated in patients currently receiving aspirin or NSAIDs because of the cumulative risk of inducing serious NSAID-related side effects. SPECIAL POPULATIONS Dosage should be adjusted for patients 65 years or older, for patients under 50 kg (110 lbs) of body weight (see DOSAGE AND ADMINISTRATION ) and for patients with moderately elevated serum creatinine (see WARNINGS ).
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
warnings
Skin Reactions NSAIDs, including ketorolac tromethamine, can cause serious skin adverse events such as exfoliative dermatitis, Stevens-Johnson Syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal. These serious events may occur without warning. Patients should be informed about the signs and symptoms of serious skin manifestations and use of the drug should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity.
warnings
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) has been reported in patients taking NSAIDs such as ketorolac tromethamine tablets. Some of these events have been fatal or life-threatening. DRESS typically, although not exclusively, presents with fever, rash, lymphadenopathy, and/or facial swelling. Other clinical manifestations may include hepatitis, nephritis, hematological abnormalities, myocarditis, or myositis. Sometimes symptoms of DRESS may resemble an acute viral infection. Eosinophilia is often present. Because this disorder is variable in its presentation, other organ systems not noted here may be involved. It is important to note that early manifestations of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not evident. If such signs or symptoms are present, discontinue ketorolac tromethamine tablets and evaluate the patient immediately.
warnings
Fetal Toxicity Premature Closure of Fetal Ductus Arteriosus: Avoid use of NSAIDs, including ketorolac tromethamine tablets, in pregnant women at about 30 weeks gestation and later. NSAIDs including ketorolac tromethamine tablets, increase the risk of premature closure of the fetal ductus arteriosus at approximately this gestational age.
warnings
Oligohydramnios/Neonatal Renal Impairment: Use of NSAIDs, including ketorolac tromethamine tablets, at about 20 weeks gestation or later in pregnancy may cause fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment. These adverse outcomes are seen, on average, after days to weeks of treatment, although oligohydramnios has been infrequently reported as soon as 48 hours after NSAID initiation. Oligohydramnios is often, but not always, reversible with treatment discontinuation. Complications of prolonged oligohydramnios may, for example, include limb contractures and delayed lung maturation. In some postmarketing cases of impaired neonatal renal function, invasive procedures such as exchange transfusion or dialysis were required. If NSAID treatment is necessary between about 20 weeks and 30 weeks gestation, limit ketorolac tromethamine tablets use to the lowest effective dose and shortest duration possible. Consider ultrasound monitoring of amniotic fluid if ketorolac tromethamine tablets treatment extends beyond 48 hours. Discontinue ketorolac tromethamine tablets if oligohydramnios occurs and follow up according to clinical practice (see PRECAUTIONS, Pregnancy ).
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
ADVERSE REACTIONS Adverse reaction rates increase with higher doses of ketorolac tromethamine. Practitioners should be alert for the severe complications of treatment with ketorolac tromethamine, such as GI ulceration, bleeding and perforation, postoperative bleeding, acute renal failure, anaphylactic and anaphylactoid reactions and liver failure (see Boxed WARNING , WARNINGS , PRECAUTIONS , and DOSAGE AND ADMINISTRATION ). These NSAID-related complications can be serious in certain patients for whom ketorolac tromethamine is indicated, especially when the drug is used inappropriately. In patients taking ketorolac tromethamine or other NSAIDs in clinical trials, the most frequently reported adverse experiences in approximately 1% to 10% of patients are: Gastrointestinal (GI) experiences including: abdominal pain Incidence greater than 10% constipation/diarrhea dyspepsia flatulence GI fullness GI ulcers (gastric/duodenal) gross bleeding/perforation heartburn nausea stomatitis vomiting Other experiences: abnormal renal function anemia dizziness drowsiness edema elevated liver enzymes headaches hypertension increased bleeding time injection site pain pruritus purpura rashes tinnitus sweating Additional adverse experiences reported occasionally (<1% in patients taking ketorolac tromethamine or other NSAIDs in clinical trials) include: Body as a Whole: fever, infections, sepsis Cardiovascular: congestive heart failure, palpitation, pallor, tachycardia, syncope Dermatologic: alopecia, photosensitivity, urticaria Gastrointestinal: anorexia, dry mouth, eructation, esophagitis, excessive thirst, gastritis, glossitis, hematemesis, hepatitis, increased appetite, jaundice, melena, rectal bleeding Hemic and Lymphatic: ecchymosis, eosinophilia, epistaxis, leukopenia, thrombocytopenia Metabolic and Nutritional: weight change Nervous System: abnormal dreams, abnormal thinking, anxiety, asthenia, confusion, depression, euphoria, extrapyramidal symptoms, hallucinations, hyperkinesis, inability to concentrate, insomnia, nervousness, paresthesia, somnolence, stupor, tremors, vertigo, malaise Reproductive, female: infertility Respiratory: asthma, cough, dyspnea, pulmonary edema, rhinitis Special Senses: abnormal taste, abnormal vision, blurred vision, hearing loss Urogenital: cystitis, dysuria, hematuria, increased urinary frequency, interstitial nephritis, oliguria/polyuria, proteinuria, renal failure, urinary retention Other rarely observed reactions (reported from postmarketing experience in patients taking ketorolac tromethamine or other NSAIDs) are: Body as a Whole: angioedema, death, hypersensitivity reactions such as anaphylaxis, anaphylactoid reaction, laryngeal edema, tongue edema (see WARNINGS ), myalgia Cardiovascular: arrhythmia, bradycardia, chest pain, flushing, hypotension, myocardial infarction, vasculitis Dermatologic: exfoliative dermatitis, erythema multiforme, Lyells syndrome, bullous reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis Gastrointestinal: acute pancreatitis, liver failure, ulcerative stomatitis, exacerbation of inflammatory bowel disease (ulcerative colitis, Crohns disease) Hemic and Lymphatic: agranulocytosis, aplastic anemia, hemolytic anemia, lymphadenopathy, pancytopenia, postoperative wound hemorrhage (rarely requiring blood transfusion see Boxed WARNING , WARNINGS , and PRECAUTIONS ) Metabolic and Nutritional: hyperglycemia, hyperkalemia, hyponatremia Nervous System: aseptic meningitis, convulsions, coma, psychosis Respiratory: bronchospasm, respiratory depression, pneumonia Special Senses: conjunctivitis Urogenital: flank pain with or without hematuria and/or azotemia, hemolytic uremic syndrome Postmarketing Surveillance Study A large postmarketing observational, nonrandomized study, involving approximately 10,000 patients receiving ketorolac tromethamine IV/IM , demonstrated that the risk of clinically serious gastrointestinal (GI) bleeding was dose-dependent (see Tables 3A and 3B ). This was particularly true in elderly patients who received an average daily dose greater than 60 mg/day of ketorolac tromethamine IV/IM (see Table 3A ). Table 3: Incidence of Clinically Serious GI Bleeding as Related to Age, Total Daily Dose, and History of GI Perforation, Ulcer, Bleeding (PUB) After up to 5 Days of Treatment with Ketorolac Tromethamine IV/IM A. Adult Patients without History of PUB Age of Patients Total Daily Dose of Ketorolac Tromethamine IV/IM ≤60 mg >60 to 90 mg >90 to 120 mg >120 mg <65 years of age 0.4% 0.4% 0.9% 4.6% ≥65 years of age 1.2% 2.8% 2.2% 7.7% B. Adult Patients with History of PUB Age of Patients Total Daily Dose of Ketorolac Tromethamine IV/IM ≤60 mg >60 to 90 mg >90 to 120 mg >120 mg <65 years of age 2.1% 4.6% 7.8% 15.4% ≥65 years of age 4.7% 3.7% 2.8% 25.0% To report SUSPECTED ADVERSE REACTIONS, contact Leading Pharma, LLC at 1-844-740-7500 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
adverse reactions table
<table width="100%" cellspacing="0" cellpadding="5" styleCode="Footnote"> <tbody> <tr> <td valign="top"> <paragraph styleCode="First TableParagraph">abdominal pain <footnote ID="L595ccd15-ce43-4ff3-a6c5-e965f3e086b5">Incidence greater than 10%</footnote> </paragraph> </td> <td valign="top"> <paragraph styleCode="First TableParagraph">constipation/diarrhea</paragraph> </td> <td valign="top"> <paragraph styleCode="First TableParagraph">dyspepsia <footnoteRef IDREF="L595ccd15-ce43-4ff3-a6c5-e965f3e086b5"/> </paragraph> </td> </tr> <tr> <td valign="top"> <paragraph styleCode="First TableParagraph">flatulence</paragraph> </td> <td valign="top"> <paragraph styleCode="First TableParagraph">GI fullness</paragraph> </td> <td valign="top"> <paragraph styleCode="First TableParagraph">GI ulcers (gastric/duodenal)</paragraph> </td> </tr> <tr> <td valign="top"> <paragraph styleCode="First TableParagraph">gross bleeding/perforation</paragraph> </td> <td valign="top"> <paragraph styleCode="First TableParagraph">heartburn</paragraph> </td> <td valign="top"> <paragraph styleCode="First TableParagraph">nausea <footnoteRef IDREF="L595ccd15-ce43-4ff3-a6c5-e965f3e086b5"/> </paragraph> </td> </tr> <tr> <td valign="top"> <paragraph styleCode="First TableParagraph">stomatitis</paragraph> </td> <td valign="top"> <paragraph styleCode="First TableParagraph">vomiting</paragraph> </td> <td valign="top"/> </tr> <tr> <td valign="top"> <paragraph styleCode="First TableParagraph">Other experiences:</paragraph> </td> <td valign="top"/> <td valign="top"/> </tr> <tr> <td valign="top"> <paragraph styleCode="First TableParagraph">abnormal renal function</paragraph> </td> <td valign="top"> <paragraph styleCode="First TableParagraph">anemia</paragraph> </td> <td valign="top"> <paragraph styleCode="First TableParagraph">dizziness</paragraph> </td> </tr> <tr> <td valign="top"> <paragraph styleCode="First TableParagraph">drowsiness</paragraph> </td> <td valign="top"> <paragraph styleCode="First TableParagraph">edema</paragraph> </td> <td valign="top"> <paragraph styleCode="First TableParagraph">elevated liver enzymes</paragraph> </td> </tr> <tr> <td valign="top"> <paragraph styleCode="First TableParagraph">headaches <footnoteRef IDREF="L595ccd15-ce43-4ff3-a6c5-e965f3e086b5"/> </paragraph> </td> <td valign="top"> <paragraph styleCode="First TableParagraph">hypertension</paragraph> </td> <td valign="top"> <paragraph styleCode="First TableParagraph">increased bleeding time</paragraph> </td> </tr> <tr> <td valign="top"> <paragraph styleCode="First TableParagraph">injection site pain</paragraph> </td> <td valign="top"> <paragraph styleCode="First TableParagraph">pruritus</paragraph> </td> <td valign="top"> <paragraph styleCode="First TableParagraph">purpura</paragraph> </td> </tr> <tr> <td valign="top"> <paragraph styleCode="First TableParagraph">rashes</paragraph> </td> <td valign="top"> <paragraph styleCode="First TableParagraph">tinnitus</paragraph> </td> <td valign="top"> <paragraph styleCode="First TableParagraph">sweating</paragraph> </td> </tr> </tbody> </table>
adverse reactions table
<table width="100%" cellspacing="0" cellpadding="5"> <col width="20%"/> <col width="20%"/> <col width="20%"/> <col width="20%"/> <col width="20%"/> <tbody> <tr> <td rowspan="2" align="center" styleCode="Botrule Lrule Rrule" valign="top"> <paragraph styleCode="First TableParagraph">Age of Patients</paragraph> </td> <td colspan="4" align="center" styleCode="Botrule Lrule Rrule" valign="top"> <paragraph styleCode="First TableParagraph">Total Daily Dose of Ketorolac Tromethamine <sup>IV/IM</sup> </paragraph> </td> </tr> <tr> <td align="center" styleCode="Botrule Lrule Rrule" valign="top"> <paragraph styleCode="First TableParagraph">≤60 mg</paragraph> </td> <td align="center" styleCode="Botrule Lrule Rrule" valign="top"> <paragraph styleCode="First TableParagraph">>60 to 90 mg</paragraph> </td> <td align="center" styleCode="Botrule Lrule Rrule" valign="top"> <paragraph styleCode="First TableParagraph">>90 to 120 mg</paragraph> </td> <td align="center" styleCode="Botrule Lrule Rrule" valign="top"> <paragraph styleCode="First TableParagraph">>120 mg</paragraph> </td> </tr> <tr> <td align="center" styleCode="Botrule Lrule Rrule" valign="top"> <paragraph styleCode="First TableParagraph"><65 years of age</paragraph> </td> <td align="center" styleCode="Botrule Lrule Rrule" valign="top"> <paragraph styleCode="First TableParagraph">0.4%</paragraph> </td> <td align="center" styleCode="Botrule Lrule Rrule" valign="top"> <paragraph styleCode="First TableParagraph">0.4%</paragraph> </td> <td align="center" styleCode="Botrule Lrule Rrule" valign="top"> <paragraph styleCode="First TableParagraph">0.9%</paragraph> </td> <td align="center" styleCode="Botrule Lrule Rrule" valign="top"> <paragraph styleCode="First TableParagraph">4.6%</paragraph> </td> </tr> <tr> <td align="center" styleCode="Botrule Lrule Rrule" valign="top"> <paragraph styleCode="First TableParagraph">≥65 years of age</paragraph> </td> <td align="center" styleCode="Botrule Lrule Rrule" valign="top"> <paragraph styleCode="First TableParagraph">1.2%</paragraph> </td> <td align="center" styleCode="Botrule Lrule Rrule" valign="top"> <paragraph styleCode="First TableParagraph">2.8%</paragraph> </td> <td align="center" styleCode="Botrule Lrule Rrule" valign="top"> <paragraph styleCode="First TableParagraph">2.2%</paragraph> </td> <td align="center" styleCode="Botrule Lrule Rrule" valign="top"> <paragraph styleCode="First TableParagraph">7.7%</paragraph> </td> </tr> </tbody> </table>
adverse reactions table
<table width="100%" cellpadding="5"> <col width="20%"/> <col width="20%"/> <col width="20%"/> <col width="20%"/> <col width="20%"/> <tbody> <tr> <td rowspan="2" align="center" styleCode="Botrule Lrule Rrule" valign="top"> <paragraph styleCode="First TableParagraph">Age of Patients</paragraph> </td> <td colspan="4" align="center" styleCode="Botrule Lrule Rrule" valign="top"> <paragraph styleCode="First TableParagraph">Total Daily Dose of Ketorolac Tromethamine <sup>IV/IM</sup> </paragraph> </td> </tr> <tr> <td align="center" styleCode="Botrule Lrule Rrule" valign="top"> <paragraph styleCode="First TableParagraph">≤60 mg</paragraph> </td> <td align="center" styleCode="Botrule Lrule Rrule" valign="top"> <paragraph styleCode="First TableParagraph">>60 to 90 mg</paragraph> </td> <td align="center" styleCode="Botrule Lrule Rrule" valign="top"> <paragraph styleCode="First TableParagraph">>90 to 120 mg</paragraph> </td> <td align="center" styleCode="Botrule Lrule Rrule" valign="top"> <paragraph styleCode="First TableParagraph">>120 mg</paragraph> </td> </tr> <tr> <td align="center" styleCode="Botrule Lrule Rrule" valign="top"> <paragraph styleCode="First TableParagraph"><65 years of age</paragraph> </td> <td align="center" styleCode="Botrule Lrule Rrule" valign="top"> <paragraph styleCode="First TableParagraph">2.1%</paragraph> </td> <td align="center" styleCode="Botrule Lrule Rrule" valign="top"> <paragraph styleCode="First TableParagraph">4.6%</paragraph> </td> <td align="center" styleCode="Botrule Lrule Rrule" valign="top"> <paragraph styleCode="First TableParagraph">7.8%</paragraph> </td> <td align="center" styleCode="Botrule Lrule Rrule" valign="top"> <paragraph styleCode="First TableParagraph">15.4%</paragraph> </td> </tr> <tr> <td align="center" styleCode="Botrule Lrule Rrule" valign="top"> <paragraph styleCode="First TableParagraph">≥65 years of age</paragraph> </td> <td align="center" styleCode="Botrule Lrule Rrule" valign="top"> <paragraph styleCode="First TableParagraph">4.7%</paragraph> </td> <td align="center" styleCode="Botrule Lrule Rrule" valign="top"> <paragraph styleCode="First TableParagraph">3.7%</paragraph> </td> <td align="center" styleCode="Botrule Lrule Rrule" valign="top"> <paragraph styleCode="First TableParagraph">2.8%</paragraph> </td> <td align="center" styleCode="Botrule Lrule Rrule" valign="top"> <paragraph styleCode="First TableParagraph">25.0%</paragraph> </td> </tr> </tbody> </table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.